title: [Effect of medical form of flocalin on the course of myocardial reperfusion injury].
abstract: In experiments on anaesthetized dogs with modeling of experimental ischemia (90 min) and reperfusion (180 min), the cardioprotective influence of the pharmacological preconditioning caused by intragastric (with a help of catheter) introduction of medicinal form (tablets) of new fluorine-containing opener of ATP-sensitive potassium channels flocalin was shown. Flocalin was introduced in a dose 2.2 mg/kg, which in the conditions of physiological norm has a minimum influence on the parameters of cardiohemodynamic. The conducted research allowed to define the changes of these parameters during development of antiischemic protective effect of pharmacological preconditioning, caused by the medicinal form of flocalin, and describes basic cardioprotective mechanisms, related to the changes of cardiohemodynamic in the dynamics of ischemia-reperfusion of myocardium. In our opinion, to positive influences of flocalin, which are possibly related to cardioprotective action, it is possible to add the prevention of an increase of general peripheral resistance, resistance of coronal vessels of heart, and relative preservation of myocardium contractility in the period of reperfusion. Also these positive effects can be explained by moderate decrease of blood pressure that decreases the loading on the damaged heart and allows to preserve cardiac emission in the first period of ischemia. One of the major indexes of development of protective mechanism of pharmacological preconditioning caused by preischemic introduction of medicinal form of flocalin is the diminishing of infarct size of myocardium in experiments with ischemia-reperfusion of myocardium on 42.53% +/- 2.91% versus control experiments.
authors.forename: R B
authors.initials: RB
authors.lastname: Strutyns'kyĭ
authors.forename: R A
authors.initials: RA
authors.lastname: Rovenets'
authors.forename: O P
authors.initials: OP
authors.lastname: Neshcheret
authors.forename: L V
authors.initials: LV
authors.lastname: Tumanovs'ka
authors.forename: T M
authors.initials: TM
authors.lastname: Boĭchuk
authors.forename: B V
authors.initials: BV
authors.lastname: Dzhuran
authors.forename: O O
authors.initials: OO
authors.lastname: Moĭbenko
mesh_terms: D000818:Animals; D002316:Cardiotonic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D004195:Disease Models, Animal; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D019157:Ischemic Preconditioning, Myocardial / Q000379:methods; D054086:KATP Channels / Q000819:agonists; D009200:Myocardial Contraction / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D009336:Necrosis; D020110:Pinacidil / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D054086:KATP Channels; C559719:N-(4-difluoromethoxyphenyl)-N'-pinacolyl-N''-cyanoguanidine; D020110:Pinacidil